OriGene Awarded NCI Contract
News Feb 03, 2014
Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA) , an approach developed by Dr. Leigh Anderson , is a novel technology that can achieve high sensitivity quantitation of proteins in clinical samples using affinity - capture SRM Mass spectrometry. One of the most desirable aspects of SISCAPA technology is that it h as the potential for simultaneous quantification of multiple proteins from a given sample making it is highly desirable in many applications to minimize sample requirements, handling, and assay costs per analyte . However, the capabilities of the SISCAPA technique are currently limited due to the scarcity of high affinity antibodies to the specific peptides that are generated by the fragmentation of the target protein before analysis.
Producing high quality antibodies for SISCAPA assays fits well with OriGene's long term goal of developing perfect assays for every human protein. The development of these antibodies is being performed in partnership with the Institute for Systems Biology (ISB) and in coordination with NCI's Clinical Proteomic Technologies for Cancer (CPTC) group. OriGene has previously collaborated with Dr. Robert Moritz , Director of Proteomics Research at ISB , for the generation of mass spec peptide profiles from over 5000 full length human proteins for inclusion in the complete human SRMAtlas . For the generation of high - affinity SISCAPA antibodies under this contract, OriGene will utilize a novel immunization strategy to develop high antibody titers in rabbits and will utilize the proteomics capabilities of the Moritz lab to identify , isolate and characterize the highest affinity antibodies suitable for SISCAP A approaches .
Dr. James Lazar, Vice President of Assay Development said, “OriGene is pleased to have been selected by NCI to receive this contract and to work with Dr. Moritz , a leader in this field. We believe that OriGene’s unique expertise in antibody development will enable the true potential of SISCAP A technology and contribute to the development of important clinical assays”.
Dr. Moritz commented : “ This is a fantastic opportunity where we continue our collaboration with OriGene and combin e our collective knowledge and expertise in antibody generation and protein chemistry to provide ‘digitized ’ antibodies for the NCI CPTC program at the NIH and support the effort of shared resources .”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.